Quest Diagnostics Inc
NYSE:DGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (2.5), the stock would be worth $167.46 (15% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3 | $196.27 |
0%
|
| 3-Year Average | 2.5 | $167.46 |
-15%
|
| 5-Year Average | 2.5 | $167.22 |
-15%
|
| Industry Average | 3.1 | $207.16 |
+6%
|
| Country Average | 2.5 | $166.81 |
-15%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 3 | 21.4 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 1.3 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 1.9 | 13.5 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 1.7 | 12.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 1.7 | 23.6 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 1.2 | 17.9 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 2.5 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 0.8 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | -117 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | -16 | 13.9 | |
| US |
|
Brightspring Health Services Inc
NASDAQ:BTSG
|
9.3B USD | 0 | 0 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Quest Diagnostics Inc
Glance View
In the rapidly evolving world of healthcare, Quest Diagnostics Inc. stands as a pivotal player, shaping the future of diagnostic services. Born out of a quest for innovation in clinical testing, Quest Diagnostics operates at the intersection of medical science and cutting-edge technology. The company has a wide-reaching network of laboratories and service centers, offering a comprehensive array of diagnostic testing solutions that range from routine blood tests to advanced genetic screening. Their services are not limited to hospitals and physician offices; they extend into a variety of sectors including pharmaceuticals, food, and global business services, completing over a hundred million clinical laboratory tests annually. Quest's robust infrastructure and commitment to precision ensure that patients and healthcare providers receive timely and accurate information that is crucial for early detection, diagnosis, and informed treatment decisions. Quest Diagnostics' revenue model is straightforward yet effective, driven primarily by service fees from its expansive menu of tests. By collaborating with insurers, healthcare providers, and employers, Quest ensures broad access to its services. Moreover, the company continually invests in research and development to expand its test portfolio and enhance the quality of its services, thus staying competitive in the fast-paced healthcare environment. Through strategic acquisitions and partnerships, Quest has broadened its geographical reach and bolstered its technological capabilities, maintaining its position as an industry leader. As healthcare increasingly leans toward personalized medicine and preventive care, Quest Diagnostics is poised to leverage its analytical prowess and deep repository of health data to drive future growth and innovation, serving as an indispensable ally in global public health.